New hope for dravet syndrome: expanded access to fenfluramine offers seizure control
NCT ID NCT04437004
First seen Apr 22, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study provides fenfluramine to people with Dravet syndrome whose seizures are not controlled by other medications. The goal is to make the drug available and check its safety. Participants must have a genetic diagnosis and have tried all available seizure drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, Los Angeles
Los Angeles, California, 90095-1752, United States
Conditions
Explore the condition pages connected to this study.